BIOMIND LABS INC. Total Liabilities
BIOMIND LABS INC. total liabilities. Based on the latest financial reports, BIOMIND LABS INC. (3XI) has total liabilities worth €1.62 Million EUR (≈ $1.89 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 3XI current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of BIOMIND LABS INC. (2021–2024)
Total liabilities of BIOMIND LABS INC. from 2021 to 2024. This chart illustrates how BIOMIND LABS INC.'s total liabilities have evolved over time, based on quarterly financial data. See 3XI free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
BIOMIND LABS INC. Competitors by Total Liabilities
The table below lists competitors of BIOMIND LABS INC. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Silver Grail Resources Ltd
V:SVG
|
Canada | CA$429.74K |
|
Tarrina Resources Limited
AU:TR8
|
Australia | AU$162.12K |
|
Taoping Inc
NASDAQ:TAOP
|
USA | $19.91 Million |
|
Ankit Metal & Power Limited
NSE:ANKITMETAL
|
India | Rs10.32 Billion |
|
N2OFF Inc
NASDAQ:NITO
|
USA | $4.67 Million |
|
XTL Biopharmaceuticals Ltd
TA:XTLB
|
Israel | ILA3.12 Million |
|
60 Degrees Pharmaceuticals, Inc. Common Stock
NASDAQ:SXTP
|
USA | $1.75 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down BIOMIND LABS INC.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is BIOMIND LABS INC.'s balance sheet.
Liquidity & Leverage Metrics
BIOMIND LABS INC. Total Liabilities Ratios Explained
BIOMIND LABS INC. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 28.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BIOMIND LABS INC.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BIOMIND LABS INC. (2021–2024)
The table below shows the annual total liabilities of BIOMIND LABS INC. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €1.34 Million ≈ $1.57 Million |
-10.95% |
| 2023-12-31 | €1.51 Million ≈ $1.76 Million |
+347.35% |
| 2022-12-31 | €336.72K ≈ $393.66K |
+0.53% |
| 2021-12-31 | €334.95K ≈ $391.60K |
-- |
About BIOMIND LABS INC.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical tria… Read more